AdociaLTS:0QAI -1.62%35 PS Ratio is 49.71 as of Jul. 03, 2026, which is 380% above its 10-year median of 10.35. GuruFocus rates LTS:0QAI with a GF Score™ of 35/100 and a GF Value™ of €0.89 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 933 Biotechnology companies, Adocia ranks worse than 78.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Adocia's share price is €4.126.
Adocia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.08. Hence, Adocia's PS Ratio for today is 49.71.
The historical rank and industry rank for Adocia's PS Ratio or its related term are showing as below:
LTS:0QAI'
s PS Ratio Range Over the Past 10 Years
Min: 1.35 Med: 10.35 Max: 93.39
Current: 50.15
During the past 13 years, Adocia's highest PS Ratio was 93.39. The lowest was 1.35. And the median was 10.35.
LTS:0QAI's PS Ratio is ranked worse than 78.78% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs LTS:0QAI: 50.15
Adocia's Revenue per Sharefor the
six
months ended in Dec. 2025 was €0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.08.
Warning Sign:
Adocia revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Adocia was -87.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -61.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -29.80% per year.
During the past 13 years, Adocia's highest 3-Year average Revenue per Share Growth Rate was 218.10% per year. The lowest was -67.90% per year. And the median was 17.00% per year.
Back to Basics: PS Ratio
Adocia (LTS:0QAI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Adocia PS Ratio Related Terms
Adocia PS Ratio Historical Data
* Premium members only.
The historical data trend for Adocia's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adocia's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adocia PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adocia's PS Ratio distribution charts can be found below:
* The bar in red indicates where Adocia's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Adocia's Share Price of today is €4.126.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adocia's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Adocia (LTS:0QAI) has a PS Ratio of 49.71 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Adocia and its competitors. This is 380% above median its historical median of 10.35. Over the past decade, Adocia's PS Ratio has ranged from 1.35 to 93.39. According to the industry distribution chart, Adocia ranks #735 out of 933 companies in the Biotechnology industry, placing it in the top 78.8%.
Is Adocia's PS Ratio too high?
Adocia's current PS Ratio of 49.71 is 380% above median its 10-year median of 10.35. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 93.39. The Biotechnology industry median PS Ratio is 9.64. Adocia's value of 49.71 is 415.7% above this industry median. Based on the distribution chart, Adocia ranks #735 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adocia has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adocia's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adocia ranks #735 out of 933 companies for PS Ratio. This places Adocia in the lower half of its industry. The industry median PS Ratio is 9.64. Adocia's value of 49.71 is 415.7% above this benchmark. Historically, Adocia's own PS Ratio has ranged from 1.35 to 93.39 over the past decade. While the company's 10-year median is 10.35 vs. the industry median of 9.64, Adocia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adocia's current PS Ratio of 49.71 is 415.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Adocia and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adocia's current PS Ratio is 49.71, which is 380% above median its own 10-year median of 10.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Based on GuruFocus' analysis, Adocia (LTS:0QAI) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.89, compared to a current price of €4.13 — trading 363.6% above its estimated fair value. The current PS Ratio is 49.71, which is 380% above median its 10-year median of 10.35 and 415.7% above the Biotechnology industry median of 9.64. Adocia's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Adocia (LTS:0QAI), the current PS Ratio is 49.71 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adocia (LTS:0QAI) Overvalued in 2026?
Based on GuruFocus' analysis, Adocia stock appears to be overvalued.
The current stock price of €4.13 is trading 363.6% above its estimated GF Value™ of €0.89.
GuruFocus considers Adocia to be Significantly Overvalued.
Key valuation signals for LTS:0QAI:
PS Ratio: 49.71 (380% above median its 10-year median of 10.35)
GF Value™: €0.89 vs. price of €4.13 (363.6% above fair value)
Industry Position: 415.7% above the Biotechnology median (#735 of 933)
No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
35GF Score
Get the complete analysis for LTS:0QAI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QAI has been successfully added to your 
